BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1080 related articles for article (PubMed ID: 17885055)

  • 1. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
    AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer detection on dynamic contrast-enhanced MRI: computer-aided diagnosis versus single perfusion parameter maps.
    Sung YS; Kwon HJ; Park BW; Cho G; Lee CK; Cho KS; Kim JK
    AJR Am J Roentgenol; 2011 Nov; 197(5):1122-9. PubMed ID: 22021504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization.
    Kim JK; Hong SS; Choi YJ; Park SH; Ahn H; Kim CS; Cho KS
    J Magn Reson Imaging; 2005 Nov; 22(5):639-46. PubMed ID: 16200542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.
    Lowry M; Zelhof B; Liney GP; Gibbs P; Pickles MD; Turnbull LW
    Invest Radiol; 2009 Sep; 44(9):577-84. PubMed ID: 19668002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence.
    Franiel T; Lüdemann L; Rudolph B; Rehbein H; Staack A; Taupitz M; Prochnow D; Beyersdorff D
    Invest Radiol; 2008 Jul; 43(7):481-7. PubMed ID: 18580330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation.
    Fennessy FM; Fedorov A; Penzkofer T; Kim KW; Hirsch MS; Vangel MG; Masry P; Flood TA; Chang MC; Tempany CM; Mulkern RV; Gupta SN
    Magn Reson Imaging; 2015 Sep; 33(7):886-94. PubMed ID: 25683515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid pancreatic lesions: characterization by using timing bolus dynamic contrast-enhanced MR imaging assessment--a preliminary study.
    Kim JH; Lee JM; Park JH; Kim SC; Joo I; Han JK; Choi BI
    Radiology; 2013 Jan; 266(1):185-96. PubMed ID: 23192779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of prostate cancer from normal prostate tissue in an animal model: conventional MRI and dynamic contrast-enhanced MRI.
    Gemeinhardt O; Lüdemann L; Prochnow D; Abramjuk C; Taupitz M; Hamm B; Beyersdorff D
    Rofo; 2005 Jul; 177(7):935-9. PubMed ID: 15973594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters.
    Riches SF; Payne GS; Morgan VA; Sandhu S; Fisher C; Germuska M; Collins DJ; Thompson A; deSouza NM
    AJR Am J Roentgenol; 2009 Dec; 193(6):1583-91. PubMed ID: 19933651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging.
    Engelbrecht MR; Huisman HJ; Laheij RJ; Jager GJ; van Leenders GJ; Hulsbergen-Van De Kaa CA; de la Rosette JJ; Blickman JG; Barentsz JO
    Radiology; 2003 Oct; 229(1):248-54. PubMed ID: 12944607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
    Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of pancreatic cancer by multiple breath-hold dynamic contrast-enhanced magnetic resonance imaging at 3.0T.
    Yao X; Zeng M; Wang H; Sun F; Rao S; Ji Y
    Eur J Radiol; 2012 Aug; 81(8):e917-22. PubMed ID: 22695786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate.
    Hansford BG; Karademir I; Peng Y; Jiang Y; Karczmar G; Thomas S; Yousuf A; Antic T; Eggener S; Oto A
    Acad Radiol; 2014 May; 21(5):569-77. PubMed ID: 24703469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study.
    Oto A; Fan X; Mustafi D; Jansen SA; Karczmar GS; Rubin DT; Kayhan A
    Acad Radiol; 2009 Oct; 16(10):1223-30. PubMed ID: 19524458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging.
    Kitajima K; Kaji Y; Fukabori Y; Yoshida K; Suganuma N; Sugimura K
    J Magn Reson Imaging; 2010 Mar; 31(3):625-31. PubMed ID: 20187206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free-breathing quantitative dynamic contrast-enhanced magnetic resonance imaging in a rat liver tumor model using dynamic radial T(1) mapping.
    Braren R; Curcic J; Remmele S; Altomonte J; Ebert O; Rummeny EJ; Steingoetter A
    Invest Radiol; 2011 Oct; 46(10):624-31. PubMed ID: 21577121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA.
    Durmus T; Vollnberg B; Schwenke C; Kilic E; Huppertz A; Taupitz M; Franiel T
    Rofo; 2013 Sep; 185(9):862-8. PubMed ID: 23888476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of dynamic contrast-enhanced MRI and diffusion-weighted MRI in patients with maxillofacial tumors.
    Kitamoto E; Chikui T; Kawano S; Ohga M; Kobayashi K; Matsuo Y; Yoshiura T; Obara M; Honda H; Yoshiura K
    Acad Radiol; 2015 Feb; 22(2):210-6. PubMed ID: 25442795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Principal component analysis of dynamic contrast enhanced MRI in human prostate cancer.
    Eyal E; Bloch BN; Rofsky NM; Furman-Haran E; Genega EM; Lenkinski RE; Degani H
    Invest Radiol; 2010 Apr; 45(4):174-81. PubMed ID: 20177391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.